Talacotuzumab
- CAS No.
- 1826831-79-1
- Chemical Name:
- Talacotuzumab
- Synonyms
- alacotuzumab;Talacotuzumab;CSL 362|||JNJ 56022473;Talacotuzumab (anti-IL-3Ra);Research Grade Talacotuzumab;Research Grade Talacotuzumab (DHD72501)
- CBNumber:
- CB38081042
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | X8JR0I7JE1 |
| NCI Drug Dictionary | talacotuzumab |
Talacotuzumab Chemical Properties,Uses,Production
Uses
Talacotuzumab (JNJ 56022473; CSL 362) is an IgG1-type fully humanized, CD123-neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has KDs of 0.43 nM, 188 nM, 46 nM, 16.8 nM for CD123, CD32b/c, CD16-158F, CD16-158V, respectively. Talacotuzumab inhibits IL-3 binding to CD123, antagonizing IL-3 signaling in target cells. Talacotuzumab has mutated the Fc region to increase affinity for CD16 (FcγRIIIa), thereby enhancing antibody-dependent cell-mediated cytotoxicity (ADCC). Talacotuzumab is highly effective in vivo reducing leukemic cell growth in acute myeloid leukemia (AML) xenograft mouse models[1][2][3][4].
in vivo
Talacotuzumab (JNJ 56022473; CSL 362; 300 μg; ip; thrice weekly for 5 weeks) results in a significant delay in tumor growth compared with an isotype control in acute myeloid leukaemia mice xenografts[1].
Talacotuzumab (1, 10, 30 mg/kg; s.c.; single injection) has maximal serum concentrations at 48 hours of ~12, 190, and 380 μg/ml at doses of 1, 10, and 30 mg/kg in naive cynomolgus monkeys, respectively[2].
| Animal Model: | Nonobese diabetic/severe combined immunodeficiency mice injected intravenously AML xenograft cells (AML-5)[1] |
| Dosage: | 300 μg |
| Administration: | IP; thrice weekly for 5 weeks |
| Result: | Resulted in a significant delay in tumor growth compared with an isotype control. |
References
[1] S J Busfield, et al. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC. Leukemia. 2014 Nov;28(11):2213-21. DOI:10.1038/leu.2014.128
[2] Shereen Oon, et al. A cytotoxic anti-IL-3Rα antibody targets key cells and cytokines implicated in systemic lupus erythematosus. JCI Insight. 2016 May 5;1(6):e86131. DOI:10.1172/jci.insight.86131
[3] Erwin M Lee, et al. Efficacy of an Fc-modified anti-CD123 antibody (CSL362) combined with chemotherapy in xenograft models of acute myelogenous leukemia in immunodeficient mice. Haematologica. 2015 Jul;100(7):914-26. DOI:10.3324/haematol.2014.113092
[4] L H Xie, et al. CD123 target validation and preclinical evaluation of ADCC activity of anti-CD123 antibody CSL362 in combination with NKs from AML patients in remission. Blood Cancer J. 2017 Jun 2;7(6):e567. DOI:10.1038/bcj.2017.52
Talacotuzumab Preparation Products And Raw materials
Raw materials
Preparation Products
Talacotuzumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| TargetMol Chemicals Inc. | +1-781-999-5354; +17819995354 | marketing@targetmol.com | United States | 32433 | 58 |
| Shanghai YuanYe Biotechnology Co., Ltd. | 021-61312847; 18021002903 | 3008007409@qq.com | China | 71826 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1566 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10308 | 58 |
| TargetMol Chemicals Inc. | 4008200310 | marketing@tsbiochem.com | China | 24989 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9868 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 6262 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11973 | 58 |
| Changsha Fuzhen Biotechnology Co.，LTD | 0731-13823398 15111215862 | 313359644@qq.com | China | 3805 | 58 |
View Lastest Price from Talacotuzumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2025-09-28 | Talacotuzumab
1826831-79-1
|
US $993.00-413.00 / mg | 98.42% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Talacotuzumab
1826831-79-1
- US $993.00-413.00 / mg
- 98.42% (SEC-HPLC)
- TargetMol Chemicals Inc.
